239 related articles for article (PubMed ID: 14551502)
1. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
Schmoll HJ
Anticancer Drugs; 2003 Oct; 14(9):695-702. PubMed ID: 14551502
[TBL] [Abstract][Full Text] [Related]
2. Novel oral fluoropyrimidines in the treatment of metastatic colorectal cancer.
Ignoffo RJ
Am J Health Syst Pharm; 1999 Dec; 56(23):2417-28; quiz 2428-9. PubMed ID: 10595802
[TBL] [Abstract][Full Text] [Related]
3. Tumor 5-FU-related mRNA Expression and Efficacy of Oral Fluoropyrimidines in Adjuvant Chemotherapy of Colorectal Cancer.
Koda K; Miyauchi H; Kosugi C; Kaiho T; Takiguchi N; Kobayashi S; Maruyama T; Matsubara H;
Anticancer Res; 2016 Oct; 36(10):5325-5331. PubMed ID: 27798895
[TBL] [Abstract][Full Text] [Related]
4. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL) and S-1: a review of their clinical development and therapeutic potential.
Hoff PM
Invest New Drugs; 2000 Nov; 18(4):331-42. PubMed ID: 11081569
[TBL] [Abstract][Full Text] [Related]
5. Oral DPD-inhibitory fluoropyrimidine drugs.
Diasio RB
Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):19-23. PubMed ID: 11098485
[TBL] [Abstract][Full Text] [Related]
6. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
7. Dihydropyrimidine dehydrogenase (DPD) activity in gastric cancer tissue and effect of DPD inhibitory fluoropyrimidines.
Usuki H; Ishimura K; Yachida S; Hagiike M; Okano K; Izuishi K; Karasawa Y; Goda F; Maeta H
Gastric Cancer; 2003; 6 Suppl 1():66-70. PubMed ID: 12775023
[TBL] [Abstract][Full Text] [Related]
8. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of oral eniluracil, 5-fluorouracil, and leucovorin in patients with advanced colorectal carcinoma.
Meropol NJ; Niedzwiecki D; Hollis D; Schilsky RL; Mayer RJ;
Cancer; 2001 Apr; 91(7):1256-63. PubMed ID: 11283924
[TBL] [Abstract][Full Text] [Related]
10. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE
Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177
[TBL] [Abstract][Full Text] [Related]
12. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase.
Schilsky RL; Kindler HL
Expert Opin Investig Drugs; 2000 Jul; 9(7):1635-49. PubMed ID: 11060767
[TBL] [Abstract][Full Text] [Related]
13. Clinical development of eniluracil: current status.
Hohneker JA
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):52-6. PubMed ID: 9830627
[TBL] [Abstract][Full Text] [Related]
14. A cost comparison of oral tegafur plus uracil/folinic acid and parenteral fluorouracil for colorectal cancer in Canada.
Maroun J; Asche C; Romeyer F; Mukherjee J; Cripps C; Oza A; Skillings J; Letarte J
Pharmacoeconomics; 2003; 21(14):1039-51. PubMed ID: 13129416
[TBL] [Abstract][Full Text] [Related]
15. [Tumoral dihydropyrimidine dehydrogenase expression and efficacy of 5-fluorouracil plus leucovorin plus UFT therapy in patients with colorectal cancer].
Ishida H; Ohsawa T; Nakada H; Yokoyama M; Inokuma S; Shirakawa K; Yamada H; Hashimoto D
Gan To Kagaku Ryoho; 2004 Jun; 31(6):883-7. PubMed ID: 15222105
[TBL] [Abstract][Full Text] [Related]
16. Drug delivery of oral anti-cancer fluoropyrimidine agents.
Miura K; Shima H; Takebe N; Rhie J; Satoh K; Kakugawa Y; Satoh M; Kinouchi M; Yamamoto K; Hasegawa Y; Kawai M; Kanazawa K; Fujiya T; Unno M; Katakura R
Expert Opin Drug Deliv; 2017 Dec; 14(12):1355-1366. PubMed ID: 28379040
[TBL] [Abstract][Full Text] [Related]
17. Regional and systemic therapies for advanced colorectal carcinoma: randomized clinical trial results.
Benson AB
Oncology (Williston Park); 1998 Oct; 12(10 Suppl 7):28-34. PubMed ID: 9830622
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic trial of weekly oral fluorouracil given with eniluracil and low-dose leucovorin to patients with solid tumors.
Grem JL; Harold N; Shapiro J; Bi DQ; Quinn MG; Zentko S; Keith B; Hamilton JM; Monahan BP; Donavan S; Grollman F; Morrison G; Takimoto CH
J Clin Oncol; 2000 Dec; 18(23):3952-63. PubMed ID: 11099325
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer: chemotherapy treatment overview.
Royce ME; Medgyesy D; Zukowski TH; Dwivedy S; Hoff PM; Pazdur R
Oncology (Williston Park); 2000 Dec; 14(12 Suppl 14):40-6. PubMed ID: 11200148
[TBL] [Abstract][Full Text] [Related]
20. New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cunningham D; Coleman R
Cancer Treat Rev; 2001 Aug; 27(4):211-20. PubMed ID: 11545541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]